Last reviewed · How we verify
concurrent temozolomide
Temozolomide is an alkylating agent that works by interfering with DNA replication in cancer cells.
Temozolomide is an alkylating agent that works by interfering with DNA replication in cancer cells. Used for Glioblastoma multiforme, Anaplastic astrocytoma.
At a glance
| Generic name | concurrent temozolomide |
|---|---|
| Sponsor | Radiation Therapy Oncology Group |
| Drug class | alkylating agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Temozolomide is a prodrug that is converted into its active form, MTIC, which then methylates DNA, leading to DNA damage and cell death. This mechanism is particularly effective in cells that are rapidly dividing, such as cancer cells.
Approved indications
- Glioblastoma multiforme
- Anaplastic astrocytoma
Common side effects
- Myelosuppression
- Nausea and vomiting
- Fatigue
- Headache
- Dizziness
Key clinical trials
- Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma (PHASE2)
- Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma (PHASE2)
- Phase 0/2 PD-Trigger Study of BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors (EARLY_PHASE1)
- Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (PHASE1)
- DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma (PHASE1, PHASE2)
- Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac (PHASE1)
- Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma (PHASE3)
- Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- concurrent temozolomide CI brief — competitive landscape report
- concurrent temozolomide updates RSS · CI watch RSS
- Radiation Therapy Oncology Group portfolio CI